# Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

> **NCT05065892** · PHASE4 · UNKNOWN · sponsor: **China National Biotec Group Company Limited** · enrollment: 1440 (estimated)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **BIOLOGICAL:** COVAX

## Key facts

- **NCT ID:** NCT05065892
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10
- **Primary completion:** 2022-01
- **Final completion:** 2022-03
- **Target enrollment:** 1440 (ESTIMATED)
- **Last updated:** 2021-10-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065892, "Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05065892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*